The dopamine radioreceptor assay--a clinical application.
The counterbalanced design in a bioequivalent study of haloperidol indicated an absence of any clinical difference between a new 20-mg dosage form and two 10-mg tablets of haloperidol (Haldol). This impression was supported by the absence of any significant behavioral changes during the four weeks when either form of the once-a-day fixed dose of 20 mg haloperidol was administered. This impression was substantiated by experiences with the dopamine receptor blocking assay, since results with this procedure also indicated the lack of any significant difference in the plasma neuroleptic equivalence of either dosage form. On the basis of present findings the assay would appear to offer promise for clinical application in the adjusting of the dosage of neuroleptic drugs, as well as in the monitoring of drug usage.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000378:metabolism*; D001519:Behavior / Q000187:drug effects; D003342:Corpus Striatum / Q000378:metabolism; D003863:Depression / Q000188:drug therapy / Q000523:psychology; D005260:Female; D006220:Haloperidol / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011869:Radioligand Assay; D011954:Receptors, Dopamine / Q000187:drug effects*; D013997:Time Factors
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D006220:Haloperidol